These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34671973)

  • 1. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
    Dhakal B; Chhabra S; Savani BN; Hamadani M
    Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
    Liu J; Zhong JF; Zhang X; Zhang C
    J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
    Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
    Chen S; van den Brink MRM
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
    Khurana A; Lin Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
    An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
    Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
    Moradi V; Omidkhoda A; Ahmadbeigi N
    Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic CAR-T cells for cancer immunotherapy.
    Chen X; Gao Y; Zhang Y
    Immunotherapy; 2024; 16(16-17):1079-1090. PubMed ID: 39378059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
    Zhao Q; Li F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates on allogeneic CAR-T cells in hematological malignancies.
    Mansoori S; Noei A; Maali A; Seyed-Motahari SS; Sharifzadeh Z
    Cancer Cell Int; 2024 Sep; 24(1):304. PubMed ID: 39227937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Del Bufalo F; Quintarelli C
    Haematologica; 2024 Jun; 109(6):1689-1699. PubMed ID: 38832424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells.
    Qasim W
    Blood; 2023 Feb; 141(8):835-845. PubMed ID: 36223560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic CAR Cell Therapy-More Than a Pipe Dream.
    Caldwell KJ; Gottschalk S; Talleur AC
    Front Immunol; 2020; 11():618427. PubMed ID: 33488631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.